When the Lyme bacterium springs a leak in the gut’s defenses

  • 2026 September 16.
  • 1265 megtekintés

Researchers have shown, in both a mouse model and blood samples from patients with acute Lyme disease, that Borrelia burgdorferi infection disrupts the gut’s defense system and produces measurable inflammatory signals in the blood. The encouraging part: in the patients studied, those signals had largely disappeared six months after antibiotic treatment.

Research conducted by: Shilpa Sachan, Giang Vu Vi Tran, Kimberly J. Olsen, Heather Kulaga, Anne Day, Hannah P. Savage, Alison W. Rebman, John N. Aucott, Isabel A. Jimenez, Cory F. Brayton, and Nicole Baumgarth

Why this matters

Many people with Lyme disease report digestive complaints or hard-to-explain, general inflammatory symptoms during the early, acute phase of illness. A new study published in 2026 in the Journal of Experimental Medicine offers a possible biological explanation: Borrelia burgdorferi (Bb) doesn’t just affect the skin, joints, or nervous system — at least in mice, it directly damages the gut’s protective barrier, and traces of this show up in patients’ blood as well.

What we already knew

Bb is known for being remarkably good at evading the immune system and persisting in tissue for long periods. In mouse studies, infection causes a rapid collapse of germinal centers — the lymph-node structures responsible for building immune responses — which prevents the body from mounting durable protection. Surprisingly, this effect extends even to the response against unrelated vaccines, such as the flu vaccine.

Earlier work also showed that even mice successfully treated with antibiotics fail to build strong immunological “memory” against the bacterium. Meanwhile, the gut’s own bacterial community (the microbiota) plays a key role in the body’s ability to produce the right antibodies (IgA, IgG) and to keep the gut wall intact — when this balance is disrupted, it can contribute to a range of chronic inflammatory conditions.

How was the study done?

The research team infected mice with Bb and, over days 3 through 140 after infection, closely examined gut tissue, inflammatory markers, and antibody and microbiota changes in blood and stool samples. The mouse findings were then compared with blood samples from 20 patients with early (acute) Lyme disease, tested both at diagnosis and again six months after completing antibiotic treatment, against 20 age- and sex-matched healthy controls.

What did they find?

The key finding is that Bb infection increased gut permeability in mice as early as day 7 — and kept it elevated for at least 140 days — producing what’s commonly called a “leaky gut.” This was preceded by mild, early gut inflammation, without major tissue damage.

At the same time, the gut’s local antibody defense (IgA) dropped significantly as early as day 7, and IgA coating of the gut bacteria (microbiota) stayed lower from day 30 onward, persisting for at least 90 days. This is especially striking given that, over the same period, total IgG antibody levels in the blood rose sharply — yet that extra antibody bound only weakly to gut bacteria (about 35% in infected mice versus about 75% in healthy mice). In other words, the body made more antibody, but it protected the gut microbiota less effectively.

The composition of the gut microbiota and levels of short-chain fatty acids (such as acetic acid) shifted meaningfully only later, around days 29 to 84 — suggesting that the barrier and antibody problems came first, and likely drove the microbiota changes, rather than the other way around.

Encouragingly, a 30-day course of ceftriaxone — an antibiotic that effectively clears Bb — significantly restored IgA coating of the gut bacteria, indicating the damage is at least partly reversible with effective treatment.

Most importantly for patients, the same pattern showed up in humans. The 20 patients with acute Lyme disease had significantly higher blood levels of two inflammation/endotoxin markers — LBP and soluble CD14 (sCD14) — at diagnosis compared with healthy controls, and these levels correlated with the number of symptoms and with a blood marker of inflammation (the neutrophil-to-lymphocyte ratio). The good news: six months after antibiotic treatment, these markers had returned to the normal range in most patients.

Figure 1: A simplified summary of the process — the steps observed in the mouse study, alongside the inflammatory markers in patients that normalized after treatment.

Worth knowing: what this study does NOT address

This study looked only at the early, acute phase of Lyme disease — it did not examine cases where symptoms persist after treatment has ended.

 

What does this mean in practice?

The findings sketch out a logical, step-by-step process: mild gut inflammation → increased gut permeability → weakened local antibody defense → secondary shifts in the gut microbiota → low-grade but measurable inflammatory signals in the blood.

The researchers suggest this raises the possibility that gut health and microbiome status could be worth monitoring more closely in Lyme disease patients — though larger studies are needed to confirm this. In the acute patients studied here, at least, the inflammatory markers largely resolved with antibiotic treatment.

SOURCE AND FURTHER READING

Sachan S, Tran GVV, Olsen KJ, Kulaga H, Day A, Savage HP, Rebman AW, Aucott JN, Jimenez IA, Brayton CF, Baumgarth N. Borrelia burgdorferi disrupts gut barrier functions and microbiota–antibody interactions. Journal of Experimental Medicine, 2026;223(9):e20252380. https://doi.org/10.1084/jem.20252380 — © 2026 Sachan et al. Open-access article published under a Creative Commons Attribution 4.0 International (CC BY 4.0) license.

This article is a more accessible summary based on the open-access, peer-reviewed study cited above. It does not replace medical advice; please consult your treating physician about treatment decisions.

(C) Lyme Borreliosis Alapítvány